DOCSLIB.ORG

Neonatal Mucosal Immunization with a Non-Living

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neonatal Mucosal Immunization with a Non-Living nature publishing group ARTICLES Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection K R a m i r e z 1,4 , Y D i t a m o 1,4 , L R o d r i g u e z 1 , W L P i c k i n g 2 , M L v a n R o o s m a l e n 3 , K L e e n h o u t s 3 a n d M F P a s e t t i 1 Safe and effective immunization of newborns and infants can significantly reduce childhood mortality, yet conventional vaccines have been largely unsuccessful in stimulating the neonatal immune system. We explored the capacity of a novel mucosal antigen delivery system consisting of non-living, non-genetically modified Lactococcus lactis particles, designated as Gram-positive enhancer matrix (GEM), to induce immune responses in the neonatal setting. Yersinia pestis LcrV, used as model protective antigen, was displayed on the GEM particles. Newborn mice immunized intranasally with GEM-LcrV developed LcrV-specific antibodies, Th1-type cell-mediated immunity, and were protected against lethal Y. pestis (plague) infection. The GEM particles activated and enhanced the maturation of neonatal dendritic cells (DCs) both in vivo and in vitro . These DCs showed increased capacities for secretion of proinflammatory and Th1-cell polarizing cytokines, antigen presentation and stimulation of CD4 + and CD8 + T cells. These data show that mucosal immunization with L. lactis GEM particles carrying vaccine antigens represents a promising approach to prevent infectious diseases early in life. INTRODUCTION due to intrinsic deficiencies of the neonatal immune system, One of the major challenges in vaccinology is the development which has a fully constituted T-cell repertoire and is capable of of safe and effective vaccines that can protect newborns and responding to antigens, but mainly to the presence of imma- infants against infectious diseases. Conventional vaccines are ture or “ inexperienced ” immune cells, particularly dendritic notoriously poorly immunogenic during the first months of cells (DCs), which have a limited capacity for antigen presenta- life, inducing immune responses that are short-lived and heav- tion and stimulation of naive T cells. 1,3 – 5 The field of neonatal ily Th2 biased. Th1-type cell-mediated immunity is modest or vaccinology has experienced unprecedented progress in recent absent, and the combination of these factors heightens the risk years, and the literature supports the assertion that newborns are of intracellular bacterial infections. 1 – 3 Even though routine indeed capable of mounting potent adaptive immunity, includ- immunization of human infants starts at 6 to 12 weeks of age, ing adult-like Th1-type immune responses to vaccine antigens, several booster doses are needed to achieve protective immunity. provided that these antigens are administered with the appropri- Mounting evidence indicates that these poor responses are not ate stimulatory signals. 1 – 3,5 – 7 1 Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine , Baltimore , Maryland , USA . 2 Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, Oklahoma , USA . 3 Mucosis BV, Groningen , The Netherlands . Correspondence: MF Pasetti ( [email protected]) 4 These authors contributed equally to the study. Received 27 July 2009; accepted 16 October 2009; published online 18 November 2009. doi:10.1038/ mi.2009.131 MucosalImmunology | VOLUME 3 NUMBER 2 | MARCH 2010 159 ARTICLES In this study, we examined the possibility of priming the neo- activate and enhance the functional capacity of neonatal DCs. natal immune system through mucosal immunization using a The expression of activation and maturation cell-surface mark- novel antigen delivery system consisting of non-living, non- ers CD80, CD86, CD40, and major histocompatibility com- genetically modified cell wall particles derived from Lactococcus plex (MHC)-class II (I-Ad) was measured on bone marrow lactis . These particles, referred to as Gram-positive enhancer (BM)-derived CD11c + cells from newborn (7-day-old) mice matrix (GEM) particles, are produced by the heat-acid treat- stimulated with L. lactis GEM particles or mock-stimulated ment of freshly grown L. lactis , a process that removes the DNA cells (Figure 1a ). To determine the strength of the activation of and most of the bacterial proteins, but leaves the peptidoglycan GEM-stimulated neonatal DCs in comparison with that of adult (PGN) envelope intact.8,9 Multiple antigens can be displayed DCs, BM-derived CD11c + cells from 6- to 8-week-old mice on the particle surface using recombinant protein and affinity were included in all experiments. All markers were upregulated technology: recombinant fusion proteins containing a vaccine in neonatal and adult DCs after GEM stimulation, compared antigen and a PGN protein anchor domain that binds with high with the mock-treated DCs ( Figure 1a ). Neonatal GEM- affinity to the bacterial PGN are produced in a suitable host cell, exposed DCs exhibited a noticeable increase in the expression purified, and then combined with naked GEM particles. The of CD86, while both CD86 and MHC-II were the markers most recombinant proteins bind tightly to the GEMs, creating anti- abundantly expressed on adult GEM-stimulated DCs. A sum- gen-displaying particles. A major advantage of the GEM parti- mary of the increases in the expression of cell-surface markers cles for neonatal immunization is their safety profile. L. lactis is a in both neonatal and adult DC exposed to the L. lactis GEMs non-pathogenic Gram-positive, lactic acid bacterium, generally or to Escherichia coli lipopolysaccharide (LPS) (used as positive recognized as safe (GRAS) and widely used in dairy products. control) is shown in Table 1 . It is noted that the upregulation of Probiotics have been safely given to newborns, 10 young children MHC-II and costimulatory molecules in both neonatal and adult in day care,11 and even critically ill children. 12 Unlike recom- GEM-stimulated DCs was remarkably similar to that induced binant live organisms, including attenuated pathogens, the by LPS under the same experimental conditions. L. lactis GEM particles do not contain DNA, i.e., there is no risk of potential reversion to a virulent form. The composition of the DC stimulated with L. lactis GEMs secreted proinflammatory GEMs also contributes to their immune-stimulating properties. cytokines As spherical particles, the GEMs can be efficiently taken up by To assess the functional capacity of the GEM-activated DCs, M cells in the epithelium above the mucosal lymphoid follicles, we examined their ability to secrete proinflammatory, Th1-pro- and the transported antigens can be delivered directly to the moting and regulatory cytokines, as these are all critical signals underlying DCs in mucosal inductive sites. Furthermore, the required for the development of an effective adaptive immune PGN envelope is a potent stimulator of innate immunity.13 response. The levels of interleukin (IL)-12p70, tumor necrosis We used Yersinia pestis LcrV as a model vaccine antigen to factor (TNF)- , IL-10, IL-6, IFN- , and MCP-1 were measured demonstrate the feasibility of successful early life immuniza- in culture supernatants from neonatal and adult BM-derived tion using the GEM platform technology. The immunogenicity CD11c + cells treated with L. lactis GEMs or LPS, or from and protective efficacy of L. lactis GEM particles displaying mock-treated cells. For all of the cytokines tested, both neona- Y. pestis LcrV was investigated in a neonatal mouse model. We tal and adult GEM-stimulated DCs had an increased capacity showed, for the first time, that intranasal immunization of new- for cytokine production as compared with mock-treated cells born mice with GEM-LcrV elicits a potent mucosal and systemic ( Figure 1b ). The levels of cytokines produced by both adult and immunity that protects against lethal systemic plague infection. neonatal mouse DCs stimulated with the L. lactis GEM parti- We also demonstrated that the L. lactis GEM particles enhance cles were comparable, suggesting that neonatal GEM-activated the maturation of neonatal CD11c + DC, and that these cells DC can reach a degree of functional activity similar to that of have increased capacity for secretion of proinflammatory and adult mature DCs. Interestingly, the fold-increases for TNF- Th1-type-promoting cytokines and can stimulate antigen-spe- and IL-6 were much higher in DC from the newborns regard- cific interferon (IFN)- -secreting CD4 + T cells. Furthermore, less of whether they were stimulated with the GEMs or LPS we showed that the GEM particles were taken up by DCs from ( Table 1 ). human newborns and that these cells also acquired a mature phenotype such that they were able to stimulate human T cells. GEM-exposed mature DCs had reduced capacity for antigen Together, these results indicate that mucosally delivered antigen- uptake displaying L. lactis GEM particles represent a highly promising During the process of maturation, DCs relent their endo- vaccine approach for immunization early in life. cytic and phagocytic activity as they become more efficient antigen-presenting cells. 14 Accordingly, we examined the RESULTS capacity of GEM-stimulated DCs to incorporate fluorescein L. lactis GEM particles induced maturation of neonatal and isothiocyanate (FITC)-dextran as a measure of antigen adult mouse DCs uptake. Both
Load more

Recommended publications
  • Molecular Biology and Biochemistry of The
    MOLECULAR BIOLOGY AND BIOCHEMISTRY OF THE REGULATION OF HRP/TYPE III SECRETION GENES IN THE CORN PATHOGEN PANTOEA STEWARTII SUBSP. STEWARTII DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Massimo Merighi, B. S., M. S. ***** The Ohio State University 2003 Dissertation Committee: Professor David L. Coplin, Adviser Approved by Professor Brian Ahmer ______________________ Professor Dietz W. Bauer Adviser Professor Terrence L. Graham Plant Pathology Copyright by Massimo Merighi 2003 ii ABSTRACT Pantoea stewartii subsp. stewartii is a bacterial pathogen of corn. Its pathogenicity depends on the expression of a Hrp/type III protein secretion/translocation system. The regulatory region of the hrp gene cluster consists of three adjacent operons: hrpXY encodes a two- component regulatory system, consisting of the response regulator HrpY and sensor PAS-kinase HrpX; hrpS encodes an NtrC-like enhancer-binding protein; and hrpL encodes an ECF sigma factor. In this study, we used genetic and biochemical approaches to delineate the following regulatory cascade: 1) HrpY activates hrpS; 2) HrpS activates hrpL; and 3) HrpL activates secretion and effector genes with ‘Hrp-box’ promoters. This pathway responds to environmental signals and global regulators. Mutant analysis showed that HrpX is required for full virulence. Deletion of its individual PAS-sensory domains revealed that they are not redundant and each may have a different role in modulating kinase activity. HrpX probably senses an intracellular signal, possibly related to nitrogen metabolism. pH, osmolarity and nicotinic acid controlled expression of hrpS independently of HrpX/HrpY.
    [Show full text]
  • Product Sheet Info
    Product Information Sheet for NR-32875 Yersinia pestis LcrV Protein, Recombinant Biosafety Level: 1 from Escherichia coli Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Catalog No. NR-32875 Public Health Service, Centers for Disease Control and This reagent is the property of the U.S. Government. Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see For research use only. Not for human use. www.cdc.gov/biosafety/publications/bmbl5/index.htm. Contributor and Manufacturer: Disclaimers: BEI Resources You are authorized to use this product for research use only. It is not intended for human use. Product Description: Yersinia pestis (Y. pestis), the causative agent of the plague, Use of this product is subject to the terms and conditions of secretes massive amounts of LcrV (low-calcium-response V the BEI Resources Material Transfer Agreement (MTA). The or V antigen) during infection. Mutations that abrogate the MTA is available on our Web site at www.beiresources.org. expression of LcrV render Y. pestis avirulent.1 LcrV is a While BEI Resources uses reasonable efforts to include multifunctional protein that is central to the activity of the type accurate and up-to-date information on this product sheet, III secretion apparatus of Y. pestis. It has no known catalytic neither ATCC® nor the U.S. Government makes any function, and its biological activity is dependent on interactions warranties or representations as to its accuracy.
    [Show full text]
  • Product Sheet Info
    Product Information Sheet for NR-796 Monoclonal Anti-Yersinia pestis Low Citation: Calcium Response V-Antigen (LcrV), Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Clone 2C6.2E4.1H8 (produced in vitro) Monoclonal Anti-Yersinia pestis Low Calcium Response V- Antigen (LcrV), Clone 2C6.2E4.1H8 (produced in vitro), NR- Catalog No. NR-796 796.” For research use only. Not for human use. Biosafety Level: 1 Appropriate safety procedures should always be used with Contributor: this material. Laboratory safety is discussed in the following Susan C. Straley, Ph.D., Department of Microbiology, publication: U.S. Department of Health and Human Services, Immunology, and Molecular Genetics, University of Public Health Service, Centers for Disease Control and Kentucky, Lexington, Kentucky, USA Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Manufacturer: Washington, DC: U.S. Government Printing Office, 2009; see BEI Resources www.cdc.gov/biosafety/publications/bmbl5/index.htm. Product Description: Disclaimers: Antibody Class: IgG1ĸ You are authorized to use this product for research use only. Monoclonal antibody prepared against the Yersinia pestis (Y. It is not intended for human use. pestis) low calcium response V-antigen (LcrV) was purified Use of this product is subject to the terms and conditions of from clone 2C6.2E4.1H8 hybridoma supernatant by protein G the BEI Resources Material Transfer Agreement (MTA). The affinity chromatography. The B cell hybridoma was MTA is available on our Web site at www.beiresources.org. generated by the fusion of NS-1 myeloma cells with immunized mouse splenocytes.
    [Show full text]
  • Antigen Immune Responses to Lcrv, A
    An Age-Old Paradigm Challenged: Old Baboons Generate Vigorous Humoral Immune Responses to LcrV, A Plague Antigen This information is current as of September 27, 2021. Sue Stacy, Amanda Pasquali, Valerie L. Sexton, Angelene M. Cantwell, Ellen Kraig and Peter H. Dube J Immunol 2008; 181:109-115; ; doi: 10.4049/jimmunol.181.1.109 http://www.jimmunol.org/content/181/1/109 Downloaded from References This article cites 44 articles, 6 of which you can access for free at: http://www.jimmunol.org/content/181/1/109.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology An Age-Old Paradigm Challenged: Old Baboons Generate Vigorous Humoral Immune Responses to LcrV, A Plague Antigen1 Sue Stacy,*‡ Amanda Pasquali,* Valerie L. Sexton,† Angelene M. Cantwell,† Ellen Kraig,2*‡ and Peter H.
    [Show full text]
  • Yersinia Pestis Lcrv Forms a Stable Complex with Lcrg and May Have a Secretion-Related Regulatory Role in the Low-Ca2ϩ Response
    JOURNAL OF BACTERIOLOGY, Feb. 1997, p. 1307–1316 Vol. 179, No. 4 0021-9193/97/$04.0010 Copyright q 1997, American Society for Microbiology Yersinia pestis LcrV Forms a Stable Complex with LcrG and May Have a Secretion-Related Regulatory Role in the Low-Ca21 Response MATTHEW L. NILLES, ANDREW W. WILLIAMS, ELZ˙BIETA SKRZYPEK, AND SUSAN C. STRALEY* Department of Microbiology and Immunology, Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0084 Received 15 August 1996/Accepted 6 December 1996 Yersinia pestis contains a virulence plasmid, pCD1, that encodes many virulence-associated traits, such as the Yops (Yersinia outer proteins) and the bifunctional LcrV, which has both regulatory and antihost functions. In addition to LcrV and the Yops, pCD1 encodes a type III secretion system that is responsible for Yop and LcrV secretion. The Yop-LcrV secretion mechanism is believed to regulate transcription of lcrV and yop operons indirectly by controlling the intracellular concentration of a secreted repressor. The activity of the secretion mechanism and consequently the expression of LcrV and Yops are negatively regulated in response to environmental conditions such as Ca21 concentration by LcrE and, additionally, by LcrG, both of which have been proposed to block the secretion mechanism. This block is removed by the absence of Ca21 or by contact with eukaryotic cells, and some Yops are then translocated into the cells. Regulation of LcrV and Yop expression also is positively affected by LcrV. Previously, LcrG was shown to be secreted from bacterial cells when the growth medium lacks added Ca21, although most of the LcrG remains cell associated.
    [Show full text]
  • Yersinia Pestis</Em>: LCRV, F1 Production, Invasion and Oxygen
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2007-12-20 Surface of Yersinia pestis: LCRV, F1 Production, Invasion and Oxygen: A Dissertation Kimberly Lea Pouliot University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Amino Acids, Peptides, and Proteins Commons, Bacteria Commons, Bacterial Infections and Mycoses Commons, Biological Factors Commons, and the Inorganic Chemicals Commons Repository Citation Pouliot KL. (2007). Surface of Yersinia pestis: LCRV, F1 Production, Invasion and Oxygen: A Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/5ayn-7c77. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/358 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. THE SURFACE OF YERSINIA PESTIS: LCRV, F1 PRODUCTION, INVASION AND OXYGEN A Dissertation Presented Kimberly Lea Pouliot Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester In partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY December 20 2007 Program of Molecular Genetics and Microbiology December 20 , 2007 THE SURFACE OF YERSINIA PESTIS: LCRV, F1 PRODUCTION, INVASION AND OXYGEN A Dissertation Presented KIMBERLY LEA POULIOT The signatures of the Dissertation Defense Committee signifies completion and a proval as to style and content of the Dissertation Jon D. Goguen , Thesis Advisor Joa n Mecsas, Member of Committee Egil Lien , Member of Committee Madelyn Schmidt, Member of Committee Neal Silverman , Member of Committee The signature of the Chair of the Committee signifies that the written dissertation meets the requirements of the Dissertation Committee John M.
    [Show full text]
  • And Adjuvant-Free Trivalent Plague Vaccine Utilizing Adenovirus-5 Nanoparticle Platform ✉ ✉ Paul B
    www.nature.com/npjvaccines ARTICLE OPEN A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform ✉ ✉ Paul B. Kilgore1, Jian Sha1,2 , Jourdan A. Andersson1, Vladimir L. Motin1,2,3,4,5 and Ashok K. Chopra1,2,4,5 A plague vaccine with a fusion cassette of YscF, F1, and LcrV encoding genes in an adenovirus-5 vector (rAd5-YFV) is evaluated for efficacy and immune responses in mice. Two doses of the vaccine provides 100% protection when administered intranasally against challenge with Yersinia pestis CO92 or its isogenic F1 mutant in short- or long- term immunization in pneumonic/bubonic plague models. The corresponding protection rates drop in rAd5-LcrV monovalent vaccinated mice in plague models. The rAd5-YFV vaccine induces superior humoral, mucosal and cell-mediated immunity, with clearance of the pathogen. Immunization of mice with rAd5-YFV followed by CO92 infection dampens proinflammatory cytokines and neutrophil chemoattractant production, while increasing Th1- and Th2-cytokine responses as well as macrophage/monocyte chemo-attractants when compared to the challenge control animals. This is a first study showing complete protection of mice from pneumonic/bubonic plague with a viral vector- based vaccine without the use of needles and the adjuvant. npj Vaccines (2021) 6:21 ; https://doi.org/10.1038/s41541-020-00275-3 1234567890():,; INTRODUCTION There have been reports of naturally occurring F1-negative Y. Yersinia pestis, the causative agent of plague, is a Tier-1 select pestis strains that can be as common as 10–16% in field sampling 18 agent and a re-emerging human pathogen1,2.
    [Show full text]
  • Timing and Targeting of Type III Secretion Translocation of Virulence Effectors in Yersinia
    Timing and targeting of Type III secretion translocation of virulence effectors in Yersinia Sofie Ekestubbe Department of Molecular Biology Umeå Centre for Microbial Research (UCMR) Laboratory for Molecular Infection Medicine Sweden (MIMS) Umeå University Umeå 2017 Copyright © Sofie Ekestubbe ISBN: 978-91-7601-639-8 Cover design: Sofie Ekestubbe Elektronisk version tillgänglig på http://umu.diva-portal.org/ Printed by: UmU Print Service, Umeå University Umeå, Sweden 2017 Till min familj Most bacteria are good guys that enable us to live happily ever after. But this is not that kind of story… TABLE OF CONTENTS Table of Contents i Abstract iii Papers Included in this Thesis iv List of Abbreviations v Sammanfattning på Svenska vii 1 Introduction 1 1.1 Virulence 3 1.2 Secretion systems in Gram-negative bacteria 4 1.2.1 Secretion across the bacterial envelope 5 1.2.2 Secretion across host cell membranes 7 1.3 The Type III Secretion System 8 1.3.1 T3SS, a secretion system that translocates 9 1.3.2 Origin and acquisition of the T3SS 9 1.3.3 The structure of the T3SS 11 1.3.3.1 Assembly of the T3SS 12 1.3.4 The function of the T3SS 13 1.3.5 Regulation of the T3SS 13 1.3.5.1 Temperature regulation 14 1.3.5.2 Cell contact 14 1.4 Secretion through the T3S organelle 15 1.4.1 The sorting platform 15 1.5 Translocation by the T3SS 16 1.5.1 The translocator proteins 16 1.5.2 Pore formation 17 1.5.3 The one-step model of translocation 18 1.5.4 The two-step model of translocation 18 1.6 Yersinia 20 1.6.1 The route of infection 20 1.6.2 Phagocytosis 20
    [Show full text]
  • Polymorphism in the Yersinia Lcrv Antigen Enables Immune Escape
    ORIGINAL RESEARCH published: 02 August 2019 doi: 10.3389/fimmu.2019.01830 Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model Catherine Daniel, Amélie Dewitte, Sabine Poiret, Michaël Marceau, Michel Simonet, Laure Marceau, Guillaume Descombes, Denise Boutillier, Nadia Bennaceur, Edited by: Sébastien Bontemps-Gallo, Nadine Lemaître and Florent Sebbane* Fabio Bagnoli, GlaxoSmithKline (Italy), Italy Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - Center for Infection and Immunity of Lille, Lille, France Reviewed by: Wayne Robert Thomas, Telethon Kids Institute, Australia Yersinioses caused by Yersinia pestis, Yersinia pseudotuberculosis, and Yersinia Anne Derbise, enterocolitica are significant concerns in human and veterinary health. The link between Institut Pasteur, France Deborah Anderson, virulence and the potent LcrV antigen has prompted the latter’s selection as a major University of Missouri, United States component of anti-Yersinia vaccines. Here, we report that (i) the group of Yersinia species Yinon Levy, Israel Institute for Biological Research encompassing Y. pestis and Y. pseudotuberculosis produces at least five different clades (IIBR), Israel of LcrV and (ii) vaccination of mice with an LcrV-secreting Lactococcus lactis only Vladimir L. Motin, protected against Yersinia strains producing the same LcrV clade as that of used for University of Texas Medical Branch at Galveston, United States vaccination. By vaccinating with engineered LcrVs and challenging mice with strains *Correspondence: producing either type of LcrV or a LcrV mutated for regions of interest, we highlight key Florent Sebbane polymorphic residues responsible for the absence of cross-protection.
    [Show full text]
  • Improved Production of Monoclonal Antibodies Against the Lcrv Antigen
    Journal of Biological Methods | 2018 | Vol. 5(4) | e100 DOI: 10.14440/jbm.2018.257 ARTICLE Improved production of monoclonal antibodies against the LcrV antigen of Yersinia pestis using FACS-aided hybridoma selection Assa Sittner1, Adva Mechaly1, Einat Vitner1, Moshe Aftalion2, Yinon Levy2, Haim Levy1, Emanuelle Mamroud2, Morly Fisher1 1Department of Infectious Diseases, Israel Institute for Biological Research, P.O. Box 19, Ness Ziona 74100, Israel 2Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, P.O. Box 19, Ness Ziona 74100, Israel Corresponding author: Morly Fisher, Email: [email protected] Competing interests: The authors have declared that no competing interests exist. Abbreviations used: BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; FACS, fluorescence-activated cell sorting; T3SS, type III secretion system Received May 20, 2018; Revision received July 17, 2018; Accepted July 19, 2018; Published November 7, 2018 ABSTRACT For about four decades, hybridoma technologies have been the “work horse” of monoclonal antibody production. These techniques proved to be robust and reliable, albeit laborious. Over the years, several major improvements have been introduced into the field, but yet, antibody production still requires many hours of labor and considerable resources. In this work, we present a leap forward in the advancement of hybridoma-based monoclonal antibody production, which saves labor and time and increases yield, by combining hybridoma technology, fluorescent particles and fluorescence-activated cell sorting (FACS). By taking advantage of the hybridomas’ cell-surface associated antibodies, we can differentiate between antigen-specific and non-specific cells, based on their ability to bind the particles. The speed and efficiency of antibody discovery, and subsequent cell cloning, are of high importance in the field of infectious diseases.
    [Show full text]
  • Polyclonal Anti-Yersinia Pestis V-Antigen (Lcrv) (Antiserum, Mice Against Plague.” Infect
    Product Information Sheet for NR-31022 Polyclonal Anti-Yersinia pestis V-Antigen Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see (LcrV) (antiserum, Goat) www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm. Catalog No. NR-31022 Disclaimers: This reagent is the property of the U.S. Government. You are authorized to use this product for research use only. It is not intended for human use. Lot No. PAS14181 (60242019) Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The For research use only. Not for human use. MTA is available on our Web site at www.beiresources.org. Contributor: While BEI Resources uses reasonable efforts to include National Institutes of Allergy and Infectious Diseases (NIAID), accurate and up-to-date information on this product sheet, National Institutes of Health (NIH) neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations Manufacturer: from scientific literature and patents are provided for ProSci Incorporated, 12170 Flint Place, Poway, California informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been Product Description: confirmed to be accurate. Antiserum to the Yersinia pestis (Y. pestis) V-antigen (LcrV) was produced by immunization of a goat with a recombinant This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. form of the V-antigen. Three bleeds were pooled and ® aliquoted to produce NR-31022. ATCC and the U.S.
    [Show full text]
  • Epitope Binning of Novel Monoclonal Anti F1 and Anti Lcrv Antibodies and Their Application in a Simple, Short, HTRF Test for Clinical Plague Detection
    pathogens Article Epitope Binning of Novel Monoclonal Anti F1 and Anti LcrV Antibodies and Their Application in a Simple, Short, HTRF Test for Clinical Plague Detection Adva Mechaly 1,*, Einat B. Vitner 1, Yinon Levy 2, David Gur 2, Moria Barlev-Gross 1, Assa Sittner 1, Michal Koren 1, Haim Levy 1 , Emanuelle Mamroud 2 and Morly Fisher 1,* 1 The Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel; [email protected] (E.B.V.); [email protected] (M.B.-G.); [email protected] (A.S.); [email protected] (M.K.); [email protected] (H.L.) 2 The Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel; [email protected] (Y.L.); [email protected] (D.G.); [email protected] (E.M.) * Correspondence: [email protected] (A.M.); [email protected] (M.F.); Tel.: +972-8-9382251 (A.M.); Tel.: +972-8-9381426 (M.F.) Abstract: Mouse monoclonal antibodies were raised against plague disease biomarkers: the bacterial capsular protein fraction 1 (F1) and the low-calcium response—LcrV virulence factor (Vag). A novel tandem assay, employing BioLayer Interferometry (BLI), enabled the isolation of antibodies against four different epitopes on Vag. The tandem assay was carried out with hybridoma supernatants, circumventing the need for antibody purification. The BioLayer assay was further adopted for Citation: Mechaly, A.; Vitner, E.B.; characterization of epitope-repetitive antigens, enabling the discovery of two unique epitopes on Levy, Y.; Gur, D.; Barlev-Gross, M.; F1.
    [Show full text]